Suppr超能文献

在给予二乙基亚硝胺(DHPN)后用硫脲处理的大鼠中甲状腺增生性病变和血清促甲状腺激素(TSH)水平的时间进程观察

Time course observation of thyroid proliferative lesions and serum TSH levels in rats treated with thiourea after DHPN initiation.

作者信息

Shimo T, Mitsumori K, Onodera H, Yasuhara K, Takahashi M, Takahashi M, Ueno Y, Hayashi Y

机构信息

Division of Pathology, National Institute of Health Sciences, Tokyo, Japan.

出版信息

Cancer Lett. 1994 Oct 14;85(2):141-9. doi: 10.1016/0304-3835(94)90267-4.

Abstract

Time course changes in serum TSH and quantitative data for thyroid proliferative lesions in male F344 rats administered N-bis(2-hydroxypropyl)nitrosamine (DHPN: 2000 mg/kg body weight, single s.c. injection) followed by 0.1% thiourea (TU), were assessed at weeks 1, 2, 4, 8, 12 and 16 of treatment. The serum T4 level in the TU group was markedly decreased at week 1 and remained significantly lowered throughout the experiment. Serum TSH levels, in contrast, were elevated up to a peak at around week 4 with a return to the normal range at week 12. Thyroid weights in the TU group were increased significantly in a treatment period-dependent manner. Histopathologically, marked hypertrophy of thyroid follicular cells occurred at the early stage of TU treatment. Proliferative lesions, such as hyperplasia and adenomas, occurred from weeks 2 and 4, respectively, and increased with the later treatment period. The cell proliferative activity of follicular cells, assessed by BrdU incorporation, was high until week 2, but then returned to normal. The initially appearing hyperplasias and adenomas were characterized by marked proliferation but this also greatly decreased at later stages when TSH was no longer elevated. The results of our study thus suggest that a high serum TSH level plays an important role in the early phase of thyroid tumorigenesis and 8 weeks treatment with test substances is sufficient for detection of thyroid tumor promoter potential in two-stage thyroid carcinogenesis models.

摘要

对雄性F344大鼠皮下注射一次N-双(2-羟丙基)亚硝胺(DHPN:2000mg/kg体重),随后给予0.1%硫脲(TU),在治疗的第1、2、4、8、12和16周评估血清促甲状腺激素(TSH)的时程变化以及甲状腺增殖性病变的定量数据。TU组血清T4水平在第1周显著降低,并在整个实验过程中持续显著低于正常水平。相比之下,血清TSH水平在第4周左右升高至峰值,在第12周恢复到正常范围。TU组甲状腺重量以依赖治疗时间的方式显著增加。组织病理学检查显示,在TU治疗早期甲状腺滤泡细胞明显肥大。增生和腺瘤等增殖性病变分别在第2周和第4周出现,并随治疗时间延长而增加。通过溴脱氧尿苷(BrdU)掺入评估的滤泡细胞增殖活性在第2周之前较高,但随后恢复正常。最初出现的增生和腺瘤以明显增殖为特征,但在TSH不再升高的后期也大幅减少。因此,我们的研究结果表明,高血清TSH水平在甲状腺肿瘤发生的早期阶段起重要作用,并且用受试物质治疗8周足以在两阶段甲状腺致癌模型中检测甲状腺肿瘤促进剂潜力。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验